Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00329186 | Study Evaluating the Pharmacokinetics of Venlafaxine ER and Desvenlafaxine SR in Healthy Subjects | PHASE3 | COMPLETED | 14 | — | — | May 1, 2006 | Jun 1, 2007 | Feb 8, 2013 | 1 | United States |
| NCT00818155 | Study Evaluating the Safety, Tolerability and Pharmacokinetics of Desvenlafaxine Succinate SR in Healthy Chinese Male and Females | PHASE1 | COMPLETED | 36 | — | — | Jan 1, 2009 | Feb 1, 2009 | Jan 29, 2013 | - | — |
| Arm | Type | Description |
|---|---|---|
| desvenlafaxine succinate SR | EXPERIMENTAL | desvenlafaxine succinate SR |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| desvenlafaxine SR | DRUG | - |
| venlafaxine ER | DRUG | - |
| desvenlafaxine succinate SR | DRUG | desvenlafaxine succinate SR |
| Placebo | OTHER | - |
Inclusion Criteria: * Healthy men and women between 18 to 55 years of age * Healthy as determined by the investigator on the basis of medical history and physical examination, laboratory test results, vital signs, and no clinically significant abnormalities on 12-lead electrocardiogram (ECG) * Hist...